Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing and able to sign a written consent form for the study
- You are 18 years or older
- Your overall health on a disability scale (ECOG) is 0 to 2
- Your prostate cancer is a type called adenocarcinoma, with no signs of “small-cell” features
- You have started or will start hormone treatment to lower testosterone (or you’ve had both testicles removed)
- Your blood, kidney, liver, and potassium levels meet required safety cutoffs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This Phase 2 trial studies whether removing the prostate (cytoreductive radical prostatectomy) and targeting visible metastases with radiation can improve outcomes for men with newly diagnosed metastatic prostate cancer who are already starting apalutamide plus hormone therapy (ADT). It’s meant to see if treating “visible spots” after the initial medication helps the cancer control last longer.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
This trial tests whether a new version of the drug abiraterone (abiraterone acetate II) works as well as the standard version for men with metastatic castration-resistant prostate cancer (MCRPC) that has progressed. You may qualify if you have already had one type of hormone therapy or chemotherapy and your cancer is spreading.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.